The American Diabetes Association (ADA) ecommends the use of either SGLT2 inhibitors or GLP-1 RA in individuals with type 2 diabetes and established ASCVD or multiple ASCVD risk factors [70]. This evidence concerns the gene GLP1R and atherosclerosis.